Last checked at 11 May 2023 11:58
genedrive plc
("genedrive", the "Group" or the "Company")
Result of General Meeting
London, UK - 11 May 2023: genedrive plc (LSE: GDR), the point of care molecular diagnostics company, announces that at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders.
For information, details of the proxy voting are shown below:
Resolutions | Votes For | Vote For (as % of votes cast) | Votes Against | Votes Against (as % of votes cast) | Votes Withheld |
1. | 15,304,609 | 88.4% | 2,001,759 | 11.6% | 1,000 |
2. | 15,300,609 | 88.4% | 2,005,759 | 11.6% | 1,000 |
3. | 15,304,609 | 88.4% | 2,001,759 | 11.6% | 1,000 |
4. | 15,300,609 | 88.4% | 2,005,759 | 11.6% | 1,000 |
The full text of the resolutions can be found in the Notice of General Meeting set out in the shareholder circular published by the Company on 24 April 2023 which is available on the Company's website www.genedriveplc.com.
For further information, please contact:
genedrive plc | +44 (0) 161 989 0245 | ||
David Budd (Chief Executive Officer) | |||
Russ Shaw (Chief Financial Officer) | |||
Peel Hunt LLP - Nominated Adviser, Joint Broker | +44 (0) 20 7148 8900 | ||
James Steel / Oliver Duckworth | |||
finnCap Ltd - Joint Broker | +44 (0) 20 7220 0500 | ||
Geoff Nash / George Dollemore |
| ||
| |||
Walbrook PR - Financial PR & IR Adviser | +44 (0) 20 7933 8780 | ||
Paul McManus / Anna Dunphy | Or Genedrive@walbrookpr.com | ||
About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company are currently developing a genetic test for CYP2C19 metaboliser status.